In Norwegian
Node leaders: Kristoffer Haugarvoll and Ragnhild Eide Skogseth
Kristoffer Haugarvoll, MD, PhD, is principal investigator (PI) in the Bergen Dementia Research Group, Associate Professor at the University of Bergen, and a consultant neurologist at the Department of Neurology, Haukeland University Hospital. Dr. Haugarvoll’s clinical expertise includes neurodegeneration, movement disorders, dementia, and neurogenetics. His main research focus is dementia and neurodegeneration, in particular dementia related to Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and the Parkinson’s disease dementia (PDD) spectrum.
Ragnhild Eide Skogseth, MD PhD, is an associate professor at the University of Bergen and a consultant geriatrician and principal investigator (PI) for dementia studies at Haraldsplass Deaconess Hospital. Dr. Skogseth’s clinical expertise includes neurodegeneration, dementia, and biomarkers. Her main research focus is dementia and neurodegeneration, in particular dementia related to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), and novel biomarkers to better diagnose these diseases.
Additional collaborator is Bettina Husebø, who is leader of the Care Node.
Node activities
Motivated by the promising finding of NAD-replenishment therapy in neurodegenerative diseases and aging, the Dementia Node has initiated clinical treatment studies to assess the neuroprotective potential of NAD-supplementation in Alzheimer’s disease. In addition, they conduct state-of-the-art biomarker research aiming at identifying subtypes of individuals with dementia, including AD and DLB, and to develop clinically applicable biomarkers for stratifying the dementias according to underlying molecular patterns.
Recent advances include one clinical trial and one prospective cohort study:
The N-DOSE study is a Phase II randomised, double-blinded dose-optimisation trial of NR in AD. The primary objective is to determine the optimal biological dose of NR for AD, so that larger trials focusing on efficacy can be designed. During 2025, 80 out of 80 planned trial participants were included, and 79 completed the follow-up. The predefined endpoints are being analysed, and the primary publication from the trial will be published in 2026.
The STRAT-COG initiative is a longitudinal population-based cohort study aiming at stratifying individuals with dementia, such as AD and DLB, according to underlying molecular patterns, and to develop biomarkers enabling patient stratification in clinical practice. The study is employing a comprehensive biomarker panel for dementia, combining existing biomarkers for AD pathology with biomarkers for neuronal loss and α-synuclein pathology.
See an overview of all Neuro-SysMed's dementia projects on the page Dementia and clinical studies.
The Dementia Node is also a partner in the ANeED study, a Phase II trial testing ambroxol in DLB (PI: Arvid Rongve), and in the ongoing Dementia Disease Initiation (DDI) study (PI: Tormod Fladby).
They are also involved in the industry-sponsored clinical trial PROGRESS-AD. This is a global Phase 2 clinical trial by GSK and Alector of AL101/GSK4527226 in participants with early Alzheimer's disease (AD).